arrow
S

Simon Francis Thomsen

bispebjerg hospital
H指数:58
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

安姆尼吉利单抗治疗 hidradenitis suppurativa 或 palmoplantar pustulosis 的安全性与药代动力学:一项 1b 期研究

2026-07-290
OAAI
Palmoplantar pustulosis is associated with greater burden and impaired quality of life compared to psoriasis only: Findings from a cross-sectional study within the Danish Skin Cohort

掌跖脓疱病与更大的疾病负担和较差的生活质量相关:丹麦皮肤队列内一项横断面研究的结果

2026-07-280
OAAI
Patients With Chronic Urticaria Have Higher Health-Care Resource Utilisation: A Danish Nationwide Case–Control Study

慢性荨麻疹患者具有较高的医疗资源利用水平:一项丹麦全国性病例对照研究

2026-02-090
PRE
Diagnostic Delay in Patients With Chronic Urticaria: Results From the Chronic Urticaria Registry (CURE)

慢性荨麻疹患者的诊断延迟:慢性荨麻疹登记研究(CURE)的结果

2026-01-140
OAAI
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis

特应性皮炎中阿布西替尼、巴瑞替尼和乌帕替尼的有效性和安全性真实世界证据:一项系统评价和Meta分析

2025-11-260
PRE
Key Predictors of Adherence to a Mobile Health App for Managing Chronic Spontaneous Urticaria
2025-11-150
OAAI
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial

Vilobelimab通过在引流隧道上的附加作用改善中重度化脓性汗腺炎的临床结局:SHINE双盲、安慰剂对照随机试验结果

2025-11-011
OAAI